NCT Number: NCT00004817
Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury.
II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury.
Looking for future studies?
Notify MeKey information
Conditions
Age range
14 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
PROTOCOL OUTLINE: This is a randomized, double blind trial involving 3 treatment groups.
On day 1, controls receive phenytoin IV over 1 hour. On days 2 through 7, controls receive 2 doses each of phenytoin and placebo daily, intravenously. From day 8 through 6 months, controls receive placebo IV 4 times daily, then placebo tablets are administered.
On day 1, the experimental group receives a loading dose of valproate sodium intravenously over 1 hour within 24 hours of injury. Then, patients are divided into 2 subgroups.
From day 2 through 1 month, one group of patients receives valproate IV 4 times daily over 1 hour until tablets are tolerated. Patients receive placebo tablets by mouth 4 times daily from month 2 through month 6.
On day 2, the other group of patients receives valproate IV 4 times daily and continues for 6 months until tablets (same dose) are tolerated.
If patients remain seizure free between day 8 and 6 months, the number of valproate or placebo tablets are tapered over 1 week.
Each patient receives a full neuropsychological and psychosocial examination at 1, 6, and 12 months after injury.
Untreated observation of patients continues until 2 years after injury.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Any patient developing the following conditions within 24 hour postinjury:
- Cortical contusion
- Depressed skull fracture
- Subdural hematoma
- Epidural hematoma
- Intracerebral hematoma
- Penetrating head wound
- Seizures occurring subsequent to head injury
--Prior/Concurrent Therapy--
- No antiseizure medication prior to injury or between the injury and study drug loading
- Surgery: No prior neurosurgical operation for which the skull and dura mater were opened
--Patient Characteristics--
- Age: 14 and over
- Hematopoietic: No abnormal coagulation profile
- Hepatic: No history of chronic or alcoholic liver disease Adequate liver function as indicated by ALT less than 1.5 times the upper limit of normal
- Other: Not pregnant No injuries greater than 24 hours old No history of seizures prior to injury No prior history of significant head injury or neurological condition requiring medical attention
Treatment and study plan
valproate sodium
DrugSponsors and collaborators
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Nih
Collaborators
- Harborview Injury Prevention and Research Center
Registry information
Important dates
- Study start
- 1991
- First posted
- Feb 25, 2000
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
NCT00004403
Brain Diseases, Central Nervous System Diseases
View Trial DetailsGenetic Study of Familial Epilepsy
NCT00006059
Brain Diseases, Central Nervous System Diseases
New York, United States
View Trial DetailsPhase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome
NCT00004776
Brain Diseases, Central Nervous System Diseases
View Trial DetailsPhase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus
NCT00004297
Brain Diseases, Central Nervous System Diseases
View Trial Details